Brussels, Belgium

Vrije Universiteit Brussel

www.vub.ac.be/en
Brussels, Belgium

The Vrije Universiteit Brussel About this sound listen is a Dutch-speaking university located in Brussels, Belgium. It has three campuses referred to as Etterbeek, Jette and Kaai .The university's name is sometimes abbreviated by "VUB" or translated to "Free University of Brussels". However, it is an official policy of the university not to use abbreviations or translations of its name, because of possible confusion with another university that has the same translated name: the French-speaking Université Libre de Bruxelles.In fact, the Vrije Universiteit Brussel was formed by the splitting in 1970 of the same Université Libre de Bruxelles, which was founded in 1834 by the Flemish-Brussels lawyer Pierre-Théodore Verhaegen. He wanted to establish a university independent from state and church, where academic freedom would be prevalent. This is today still reflected in the university's motto Scientia vincere tenebras, or Conquering darkness by science, and in its more recent slogan Redelijk eigenzinnig , or Reasonably opinionated. Accordingly, the university is pluralistic — it is open to all students on the basis of equality regardless of their ideological, political, cultural or social background – and it is managed using democratic structures, which means that all members – from students to faculty – participate in the decision-making processes.The university is organised into 8 faculties that accomplish the three central missions of the university: education, research, and service to the community. The faculties cover a broad range of fields of knowledge including the natural science, classics, life science, social science, humanities, and engineering. The university provides bachelor, master, and doctoral education to about 8,000 undergraduate and 1,000 graduate students. It is also a strongly research-oriented institute, which has led to its top-189th position among universities worldwide. Its research articles are on average more cited than articles by any other Flemish university. Wikipedia.


Time filter

Source Type

Patent
Vrije Universiteit Brussel and The General Hospital Corporation | Date: 2017-03-22

The invention relates to polynucleotides suitable for reducing or eliminating the expression of expanded repeat RNA (CUGexp) of the dystrophy myotonic-protein kinase (DMPK) gene in a cell of a DM-1 patient. The polynucleotides are a combination of a polynucleotide for a site specific nuclease targeting the dystrophy myotonic- protein kinase (DMPK) gene locus, and a donor polynucleotide having 5 and 3 regions which are homologous with the sequence of DMPK gene which flank the target site of the nuclease. The invention further relate to in vivo and in vitro methods to reduce or eliminate CTG repeats in the DMPK gene. The invention further relates to the medical use of polynucleotides and cells for treating DM-1 patient.


Patent
Vrije Universiteit Brussel | Date: 2017-04-26

A micro-reactor system for contacting fluids is described. The system comprises a first microfluidic channel structure for guiding a first fluid to at least one output nozzle thus generating a first sub-flow, a second microfluidic channel structure for guiding a second fluid to at least a second output nozzle thus generating a second sub-flow, said first output nozzle being aligned with said second output nozzle and arranged for contacting the first sub-flow and the second sub-flow. The micro-reactor comprises at least a third microfluidic channel structure for at least a third,inert,fluid generating at least a third sub-flow arranged to be positioned adjacent at least the first and/or the second sub- flows so as to act as a wall between said first and/or second sub-flows.


Patent
Vrije Universiteit Brussel | Date: 2017-06-21

The present invention relates to a reservoir computing device comprising a cascade of at least two reservoir computing blocks, each reservoir computing block comprising- summing means for making a sum of a block input signal and a delayed signal output by the reservoir computing block,- a digital filter structure arranged for applying a non-linear function to said sum and for adding to a non-linear function output a filtered version of a preceding non-linear function output, yielding a digital filter structure output signal,- a delay line structure arranged for receiving as input the digital filter structure output signal and for outputting a delay line structure output signal to a readout layer, said delay line structure comprising a plurality of delay elements arranged for outputting the delayed signal being a delayed version of the digital filter structure output signal,whereby the block input signal is in the first reservoir computing block of the cascade a signal applied to the reservoir computing device and whereby in each subsequent reservoir computing block of the cascade the block input signal is, according to a given combining pattern, a delayed version of the signal applied to said reservoir computing device, the delay line structure output signal applied to said readout layer by the previous reservoir computing block in the cascade or a combination thereof.


The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (VHH) or a functional fragment thereof, wherein said VHH or a functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor, e.g. HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for detection, imaging, prognosis and diagnosis of cancer as well as for predicting patient response(s) to therapeutics.


The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (VHH) or functional fragments thereof, wherein said VHH or functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor or cancer cell, e.g. HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions,for use in methods for the prevention and/or treatment of cancer.


The present disclosure provides a telecommunications device comprising an electrical balance duplexer connected to an output node of a transmission path, an input node of a receive path, an antenna and a tuneable impedance. The electrical balance duplexer is configured to isolate the transmission path from the receive path by tuning the tuneable impedance by means of a tuning circuit. The tuning circuit comprises voltage amplitude detectors at the connections between the electrical balance duplexer and the transmission path, the receive path and the tuneable impedance, voltage phase difference detectors between the connections between the electrical balance duplexer and the transmission path, the receive path and the tuneable impedance, an impedance sensor at the connection between the electrical balance duplexer and the tuneable impedance, and a processing unit configured for calculating an optimal impedance value from the detector data, and for tuning the tuneable impedance towards said optimal impedance value.


Patent
Vib Vzw, Vrije Universiteit Brussel and Stanford University | Date: 2017-01-18

The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.


Patent
Vrije Universiteit Brussel | Date: 2017-03-24

A system for conversion or amplification using quasi-phase matched nonlinear optical wave-mixing includes a first radiation source for providing a pump radiation beam, a second radiation source for providing a signal radiation beam, a bent structure for receiving the pump radiation beam and the signal radiation beam, and an outcoupling radiation propagation portion for coupling out an idler radiation beam generated in the bent structure. A radiation propagation portion of the bent structure is made of a uniform three-dimensional material at least partly covered by a two-dimensional or quasi-two-dimensional material layer and has a dimension taking into account the spatial variation of the nonlinear optical susceptibility along the radiation propagation portion as experienced by radiation traveling along the bent structure for obtaining quasi-phase matched nonlinear optical wave-mixing in the radiation propagation portion. The dimension thereby is substantially inverse proportional with the linear phase mismatch for the nonlinear optical process.


Patent
CommScope, ADC Telecommunications and Vrije Universiteit Brussel | Date: 2017-07-26

A self-centering structure (300) for aligning optical fibers (308) desired to be optically coupled together is disclosed. The self-centering structure (300) including a body (310) having a first end (312) and a second end (314). The first end (312) defines a first opening (303) and the second end (314) defines a second opening (304). The self-centering structure (300) includes a plurality of groove structures (306) integrally formed in the body (310) of the self-centering structure for receiving the optical fibers (308) and a fiber alignment region (305) positioned at an intermediate location between the first and second ends (312, 314) to facilitate centering and alignment of the optical fibers (308). The self-centering structure (300) further includes a plurality of cantilever members (322) arranged and configured on opposing sides of the fiber alignment region (305). Each of the plurality of cantilever members (322) are aligned with a respective one of the plurality of groove structures (306). The plurality of cantilever members (322) include a first plurality of cantilever members (322a) adjacent the first end (312) of the self-centering structure (300) and a second plurality of cantilever members (322b) adjacent the second end (314) of the self-centering structure (300). The plurality of cantilever members (322) is flexible and configured for urging the optical fibers (308) into their respective groove structures (306).


Muyldermans S.,Vrije Universiteit Brussel
Annual Review of Biochemistry | Year: 2013

Sera of camelids contain both conventional heterotetrameric antibodies and unique functional heavy (H)-chain antibodies (HCAbs). The H chain of these homodimeric antibodies consists of one antigen-binding domain, the VHH, and two constant domains. HCAbs fail to incorporate light (L) chains owing to the deletion of the first constant domain and a reshaped surface at the VHH side, which normally associates with L chains in conventional antibodies. The genetic elements composing HCAbs have been identified, but the in vivo generation of these antibodies from their dedicated genes into antigen-specific and affinity-matured bona fide antibodies remains largely underinvestigated. However, the facile identification of antigen-specific VHHs and their beneficial biochemical and economic properties (size, affinity, specificity, stability, production cost) supported by multiple crystal structures have encouraged antibody engineering of these single-domain antibodies for use as a research tool and in biotechnology and medicine. © 2013 by Annual Reviews. All rights reserved.

Loading Vrije Universiteit Brussel collaborators
Loading Vrije Universiteit Brussel collaborators